# program

### Saturday, May 17

8:15-8:20 a.m.	Welcome from the AGA Institute President Nicholas F. LaRusso, MD, AGAF	11:40 a.mNoon	Clostridium Difficile Colitis: Emergence of New Strains and Novel Therapies	
8:20-8:30 a.m.	Introduction Prateek Sharma, MD	Noon-12:20 p.m.	Ciáran P. Kelly, MD Controversy: Gut Microflora, GI Diseases and Probiotics	
Session I – Moving Down the Esophagus Moderator: Prateek Sharma, MD		– 12:20–12:25 p.m. 12:30–1:30 p.m.	Michael Camilleri, MD, AGAF Moderator's Summary Luncheon Breakout Sessions	
<b>Challenging Case:</b> A 52-year-old patient with reflux symptoms despite high dose PPI therapy.			(see separate listing for selections)	
8:30-8:50 a.m.	Esophageal Physiology and Function Testing 2008 Peter J. Kahrilas, MD, AGAF	Session III – Inflammatory Bowel Disease Moderator: Maria T. Abreu, MD		
8:50-9:10 a.m.	Beyond PPIs in GERD: What to do Next? John Dent, MD, PhD	Challenging C	Challenging Case: A 40-year-old man with Crohn's disease and recurrent pelvic abscesses.	
9:10-9:30 a.m.	<i>H. pylori</i> , Gastritis and Gastric Cancer: Bacterial, Host and Environmental Factors M. Brian Fennerty, MD, AGAF	1:45–2:05 p.m.	Role of Genes, Cytokines and Environment in IBD Scott E. Plevy, MD	
9:30-9:50 a.m.	Minimizing GI Risk in NSAID and ASA Users Loren A. Laine, MD	2:05-2:25 p.m.	New Diagnostic Techniques for IBD: Serology, Imaging, and Capsule Asher M. Kornbluth, MD, AGAF	
9:50-10:10 a.m.	Controversy: Management of Dysplasia in Barrett's Esophagus Richard E. Sampliner, MD, AGAF	2:25-2:45 p.m.	Biologics in IBD: First Line Therapy? William J. Sandborn, MD	
10:10-10:15 a.m.	······································	2:45-3:05 p.m.	Surgical Approach to Crohn's Disease Victor W. Fazio, MD	
10:15–10:35 a.m.	Refreshment Break	3:05–3:25 p.m.	Controversy: Dysplasia in IBD: Screening, Prevention and Treatment	
Session II – Beyond the Pylorus Moderator: Helen M. Shields, MD, AGAF			David T. Rubin, MD	
		3:25-3:30 p.m.	Moderator's Summary	
<b>Challenging Case:</b> A 32-year-old woman with gas, bloating and diarrhea.		3:30-4:00 p.m.	Refreshment Break	
0	Celiac Sprue: Over or Under Diagnosis? Sheila E. Crowe, MD, AGAF	4:00–5:30 p.m.	Clinical Challenge Sessions (see separate listing for selections)	

11:00–11:20 a.m. Irritable Bowel Syndrome: Putting the ROME Criteria into Practice Charlene M. Prather, MD, AGAF

11:20–11:40 a.m. Chronic Diarrhea: What's New? Henry J. Binder, MD, AGAF

## **Course Information**

Attend this two-day course and learn valuable information about the challenges and controversies surrounding major GI and liver disorders. The course takes an innovative approach in its review of everyday diagnostic and treatment challenges. Each general session will address a specific GI or liver topic beginning with a brief, thought-provoking case study. Renowned experts in the field will then discuss diagnostic, pathogenetic and treatment-related issues related to the topic and conclude the session by addressing a relevant controversy. Don't miss this opportunity to gain a better understanding of the issues surrounding CT colonography, nonalcoholic fatty liver disease, IBD, gut microflora and probiotics, hepatocellular carcinoma screening and more.

**Simultaneous Spanish and** 

**Japanese Translation Available.** 

#### Sunday, May 18

	-			
Session IV – Gastrointestinal Cancers: What's New? Moderator: David A. Lieberman, MD		Noon-12:20 p.m.	Controversy: Nonalcoholic Fatty Liver: Is Any Treatment Worthwhile? Nathan M. Bass, MD, PhD	
<b>Challenging Case:</b> A 38-year-old patient with a family history of colon cancer.		12:20–12:25 p.m.	Moderator's Summary	
		12:30–1:30 p.m.	Luncheon Breakout Sessions	
8:30-8:50 a.m.	-8:50 a.m. Colon Cancer Screening and Surveillance Douglas K. Rex, MD		(see separate listing for selections)	
8:50–9:10 a.m.	FAP and Other High-Risk Cancer Populations Sapna Syngal, MD, MPH	Session VI – Hepatology Moderator: J. Eileen Hay, MD		
9:10-9:30 a.m.	The Rising Incidence of Esophageal Cancer: Genes or Fat? Nicholas J. Shaheen, MD, MPH, AGAF	<b>Challenging Case:</b> A 35-year-old patient with chronic Hepatitis B.		
9:30-9:50 a.m.	Pancreatic Cancer: Targeting Precancerous Lesions, Their Etiology and Management	1:45-2:05 p.m.	Hepatitis B: Emerging Therapies in 2008 Anna S.F. Lok, MD, AGAF	
9:50–10:10 a.m.	David C. Whitcomb, MD, PhD Controversy: CT Colonography—	2:05-2:25 p.m.	Hepatitis C: Beyond the Standard Responder Norah A. Terrault, MD	
9.50-10.10 a.m.	Ready for Screening Patients? Don C. Rockey, MD, AGAF	2:25-2:45 p.m.	Liver Transplant: Timing, Selection and Survival James F. Trotter, MD	
10:10-10:15 a.m.	Moderator's Summary	2:45-3:05 p.m.	Iron Overload Syndromes: Genetic Testing, Hepcidin and Beyond Bruce R. Bacon, MD	
10:15-10:35 a.m.	Refreshment Break			
Session V – The Epidemic of Obesity Moderator: Kenneth R. McQuaid, MD, AGAF		3:05–3:25 p.m.	Controversy: Hepatocellular Carcinoma— Is Screening Effective? Hashem B. El Serag, MD, MPH	
<b>Challenging Case:</b> A 45-year-old obese patient wants to lose weight.		3:25–3:30 p.m.	Moderator's Summary	
		3:30-4:00 p.m.	Refreshment Break	
10:40-11:00 a.m.	Fad Diets and Medicines: Do They Work? Samuel Klein, MD	4:00-5:30 p.m.	Clinical Challenge Sessions (see separate listing for selections)	
11:00-11:20 a.m.	Endoscopic and Surgical Approaches to Weight Loss Anthony M. Kalloo, MD			
11:20-11:40 a.m.	Obesity, Weight Loss and Liver Function Andrea Reid, MD			
11:40 a.mNoon	GI Complications of Bariatric Surgery Jacques M. E. Deviere, MD			

### Learning Objectives

## Upon completion of this course, participants will be able to:

- Understand the various options available for the management of pancreatic cancer, esophageal motility disorders, portal hypertension and chronic constipation.
- Identify areas of controversy associated with Barrett's esophagus, inflammatory bowel disease, colorectal cancer, hepatocellular carcinoma and fatty liver disease.
- Discuss advances in the evaluation and treatment of hepatitis B, C, celiac sprue and iron overload syndromes.
- Evaluate the approaches to the diagnosis of eosinophilic esophagitis, dyspepsia and chronic diarrhea.
- List the newest modalities of endoscopy and noninvasive imaging of the gastrointestinal tract and liver.
- Employ alternative methods in managing gastroesophageal reflux, irritable bowel syndrome, obesity, and *C. difficile* colitis.
- Understand the endoscopic therapies that are currently available for gastrointestinal malignancies, pancreatic cysts and obesity.

### Luncheon Breakouts: 12:30-1:30 p.m.

Choose from 17 different topics! Select a different session for each day of the course. Sessions are assigned on a first-come, first-served basis. Lunch without learning option is available. Note: Luncheon Breakouts are offered only in English.

#### (L1XX-Saturday; L2XX-Sunday)

L101; L201	Eosinophilic Esophagitis, David A. Katzka, MD
L102; L202	ERCP: Difficult Cannulations Made Easy, Guido Costamagna, MD
L103; L203	Hemorrhoids, Fissures, and Fecal Incontinence, Satish S.C. Rao, MD, PhD, AGAF
L104; L204	Endoscopic Mucosal Resection, Kenneth K. Wang, MD, AGAF
L105; L205	Autoimmune Pancreatitis, Alphonso Brown, MD
L106; L206	Women's Health, Jacqueline L. Wolf, MD
L107; L207	Barrett's Esophagus: Screening, Surveillance and Ablation, Stuart J. Spechler, MD, AGAF
L108; L208	Nonalcoholic Fatty Liver Disease: What to Tell Your Patients, Nathan M. Bass, MD, PhD
L109; L209	Capsule Endoscopy, Norman E. Marcon, MD
L110; L210	Functional Dyspepsia: Evidence-Based Management, William D. Chey, MD, AGAF
L111; L211	Breakthroughs in Endoscopic Techniques and NOTES, Anthony N. Kalloo, MD
L112; L212	Non-Variceal Upper GI Bleeding, Loren A. Laine, MD
L113; L213	Extra-Esophageal GERD: Fact or Fiction, John M. Inadomi, MD, AGAR
L114; L214	Endoscopic Diagnosis and Management of Chronic Pancreatitis, Jacques M.E. Deviere, MD
L115; L215	PBC and PSC, John M. Vierling, MD
L116; L216	Clinical Problems Caused by Gastrointestinal Hormones, Robert T. Jensen, MD
L117; L217	Drug-Induced Liver Disease, Laurie DeLeve, MD, PhD
L118; L218	Lunch only (no breakout session)
L119; L219	Not attending a lunch session

#### Clinical Challenge Sessions: 4:00–5:30 p.m.

Choose from ten exciting sessions! Pick a different session for each day of the course. Sessions are assigned on a first-come, first-served basis. Note: Clinical Challenge sessions are offered only in English.

#### (C1XX-Saturday; C2XX-Sunday)

C101; C201	Complex Issues in IBD: Pregnancy, Fistulae, Pouchitis, Maria T. Abreu, MD and William J. Sandborn, MD
,	Acute Necrotizing Pancreatitis, Horst Neuhaus, MD and Amit Rastogi, MD
C103; C203	Esophageal Motility Disorders, Ajay Bansal, MD and

C104; C204 Difficult Management Problems in Viral Hepatitis, Norah A. Terrault, MD and Emmet B. Keeffe, MD, AGAF

Peter J. Kahrilas, MD, AGAF

- C105; C205 Endoscopic Diagnosis and Staging of GI Malignancies, Paul Fockens, MD, PhD and Jacques J.H.G.M. Bergman, MD, PhD
- C106; C206 IBS: New Insights into Pathogenesis and Therapies, William D. Chey, MD, AGAF and Charlene M. Prather, MD, AGAF
- C107; C207 Portal Hypertension: Standards of Practice and New Treatments, Guadalupe Garcia-Tsao, MD and Vijay H.Shah, MD
- C108; C208 Cystic Lesions of the Pancreas, R. Paul O'Farrell, MD, FRACP and Michael B. Wallace, MD, MPH
- C109; C209 Chronic Constipation and Colonic Pseudo-Obstruction, Lin Chang, MD and Satish S.C. Rao, MD, PhD, AGAF
- C110; C210 Evaluation of Liver Masses, K. Rajender Reddy, MD and Claude B. Sirlin, MD
- C111; C211 Not attending a clinical challenge session.

The **Luncheon Breakout** and **Clinical Challenge** sessions are ticketed. You must indicate your choice(s) for these sessions using the codes listed above when completing your DDW registration form in order for your registration to be processed. If you are not going to attend a Luncheon Breakout or Clinical Challenge session, be sure to check the box on the registration form indicating that you will not attend.

### **Course Highlights**

- Novel format that presents challenging cases and controversial issues on a variety of GI and liver topics.
- Clinically focused program with immediately applicable information.
- Flexible, customized learning formats—from large lectures to small group sessions.
- Opportunity to interact with an internationally renowned faculty.

- Earn up to 15 AMA PRA Category 1 Credit(s)™.
- Take-home syllabus that includes detailed summaries of all sessions, including abstracts, key points, references, slides, graphs, charts and tables. Additional copies are available for purchase.

Contact Ashley Mees, Director of Education, at (301) 941-9786 or amees@gastro.org for program-related information.

